Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests (2016 - 2018)
Vertex Pharmaceuticals has reported Income from Non-Controlling Interests over the past 8 years, most recently at -$25.4 million for Q4 2018.
- Quarterly results put Income from Non-Controlling Interests at -$25.4 million for Q4 2018, down 1794.27% from a year ago — trailing twelve months through Sep 2019 was -$25.4 million (down 248.38% YoY), and the annual figure for FY2018 was -$9.8 million, up 94.3%.
- Income from Non-Controlling Interests for Q4 2018 was -$25.4 million at Vertex Pharmaceuticals, down from -$290000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for VRTX hit a ceiling of $28.4 million in Q2 2016 and a floor of -$188.3 million in Q3 2017.
- Median Income from Non-Controlling Interests over the past 5 years was -$98000.0 (2015), compared with a mean of -$10.7 million.
- Biggest five-year swings in Income from Non-Controlling Interests: skyrocketed 5741.84% in 2016 and later tumbled 26956.75% in 2017.
- Vertex Pharmaceuticals' Income from Non-Controlling Interests stood at $4.2 million in 2014, then crashed by 122.39% to -$938000.0 in 2015, then tumbled by 452.88% to -$5.2 million in 2016, then soared by 128.94% to $1.5 million in 2017, then plummeted by 1794.27% to -$25.4 million in 2018.
- The last three reported values for Income from Non-Controlling Interests were -$25.4 million (Q4 2018), -$290000.0 (Q3 2018), and -$1.1 million (Q2 2018) per Business Quant data.